In the RTOG 94-05 (INT 0123) study comparing stand ard-dose (50.4 Gy) versus high-dose (64.8 Gy) radiation with concurrent cisplatin and 5-fluorouracil for esophageal cancer, what was the difference in persistence of locoregional disease?
In the RTOG 94-05 (INT 0123) study comparing stand ard-dose (50.4 Gy) versus high-dose (64.8 Gy) radiation with concurrent cisplatin and 5-fluorouracil for esophageal cancer, what was the difference in persistence of locoregional disease?